Tag: ILUMYA
Sun Pharma announces US FDA acceptance of sBLA application for ILUMYA...
If the sBLA is approved, expansion into psoriatic arthritis would build on the established clinical experience of ILUMYA as an IL-23 inhibitor for moderate-to-severe plaque psoriasis; FDA decision expected by October 29, 2026
Sun Pharma’s phase 3 trials of ILUMYA support potential U.S. submission...
Both pivotal studies met their primary endpoint with statistically significant improvements based on ACR20 response rates at Week 24 with tildrakizumab 100 mg (ILUMYA) compared to placebo
Sun Pharma announces 5-year sustained efficacy & safety results for its...
ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis.......................
Sun Pharma’s plaque psoriasis drug ILUMYA gets approval in Japan
The drug offers a new treatment option with only one injection every 12 weeks for Japanese patients who struggle everyday with the chronic nature of plaque psoriasis..........................
Sun Pharma inks deals with Hikma Pharma over distribution of psoriasis...
Sun Pharma and Hikma have entered into an exclusive licensing agreement for ILUMYA for the Middle East and North Africa regions...................